Q-omics provides the consensus-scored RP1 profile across patient tissues and cancer cell-line models. RP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RP1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RP1 RNA expression shows 12,047 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where RP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RP1 survival associations across molecular data types. RP1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (12) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RP1 RNA expression–survival associations across cancer types. High RP1 expression shows unfavorable associations in ACC, KIRC, CESC, BLCA and PAAD, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RP1 RNA expression.
This table summarizes RP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RP1 shows lower tumor expression in KIRC, LUSC, LUAD and KICH and higher tumor expression in COAD and THCA. The KIRC box plot shows higher RP1 RNA expression in normal versus tumor tissue (log2 FC = −0.289, t-test p < 0.001).
This table shows molecular features associated with RP1 in patient tissues and cancer cell lines. In patient samples, RP1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
